Meeder Asset Management’s Galectin Therapeutics GALT Stock Holding History

Meeder Asset Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,817	Closed	-$9.12K	–	898
2024 Q1	$9.12K	Hold	3,817	–	–	﹤0.01%	565
2023 Q4	$6.34K	Hold	3,817	–	–	﹤0.01%	428
2023 Q3	$7.33K	Hold	3,817	–	–	﹤0.01%	439
2023 Q2	$5.5K	Hold	3,817	–	–	﹤0.01%	463
2023 Q1	$8.02K	Hold	3,817	–	–	﹤0.01%	515
2022 Q4	$4.31K	Sell	3,817 -1,818	-32%	-$2.42K	﹤0.01%	706
2022 Q3	$9K	Sell	5,635 -322	-5%	-$602	﹤0.01%	1357
2022 Q2	$7K	Sell	5,957 -2,037	-25%	-$2.93K	﹤0.01%	1502
2022 Q1	$13K	Buy	+7,994	New	+$15.5K	﹤0.01%	1446
2021 Q4	–	Sell	-7,783	Closed	-$30K	–	1613
2021 Q3	$30K	Buy	7,783 +2,866	+58%	+$9.71K	﹤0.01%	1273
2021 Q2	$16K	Buy	+4,917	New	+$17.5K	﹤0.01%	1527
2020 Q2	–	Sell	-186	Closed	–	–	2190
2020 Q1	$0	Buy	+186	New	+$453	﹤0.01%	2387
2019 Q4	–	Sell	-19	Closed	–	–	2319
2019 Q3	$0	Buy	+19	New	+$69	﹤0.01%	2186

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Meeder Asset Management's GALT Position: Q2 2024 in Review

Meeder Asset Management sold out of Galectin Therapeutics (GALT) in Q2 2024, closing a stake of 3,817 shares — an estimated $9.12K sold.

Meeder Asset Management first reported a position in GALT in Q3 2019 and held it in 13 quarters. The position peaked at $30K in Q3 2021. 73 funds tracked by Wall St. Rank hold GALT as of Q2 2024.

Meeder Asset Management reported no remaining Galectin Therapeutics position as of Q2 2024 after selling out during the quarter.
Meeder Asset Management sold 3,817 Galectin Therapeutics shares in Q2 2024, an estimated $9.12K.
Meeder Asset Management first reported a position in Galectin Therapeutics in Q3 2019 and held it in 13 quarters.
Meeder Asset Management's Galectin Therapeutics position peaked at $30K in Q3 2021.
73 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2024.

Based on Meeder Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.